** Shares of Neurizon Therapeutics NUZ.AX rise as much as 3.2% to A$0.160, their biggest intraday pct gain since June 26
** The biotechnology co enters into a global licensing agreement with Elanco Animal Health ELAN.N
** Agreement is for exclusive rights to Elanco's data package and related intellectual property for Monepantel, the active pharmaceutical ingredient in co's NUZ-001, a formulation used in neurodegeneration applications
** YTD, shares of co down 5.9%
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。